MANNKIND CORP (MNKD) Stock Price & Overview
NASDAQ:MNKD • US56400P7069
Current stock price
The current stock price of MNKD is 2.57 USD. Today MNKD is up by 0.39%. In the past month the price decreased by -8.87%. In the past year, price decreased by -44.85%.
MNKD Key Statistics
- Market Cap
- 791.817M
- P/E
- 42.83
- Fwd P/E
- 48.25
- EPS (TTM)
- 0.06
- Dividend Yield
- N/A
MNKD Stock Performance
MNKD Stock Chart
MNKD Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to MNKD. When comparing the yearly performance of all stocks, MNKD is a bad performer in the overall market: 94.85% of all stocks are doing better.
MNKD Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to MNKD. While MNKD is still in line with the averages on profitability rating, there are concerns on its financial health.
MNKD Earnings
On February 26, 2026 MNKD reported an EPS of -0.05 and a revenue of 111.95M. The company missed EPS expectations (-439.47% surprise) and beat revenue expectations (12.45% surprise).
MNKD Forecast & Estimates
15 analysts have analysed MNKD and the average price target is 7.65 USD. This implies a price increase of 197.67% is expected in the next year compared to the current price of 2.57.
For the next year, analysts expect an EPS growth of -6.55% and a revenue growth 36.86% for MNKD
MNKD Groups
Sector & Classification
MNKD Financial Highlights
Over the last trailing twelve months MNKD reported a non-GAAP Earnings per Share(EPS) of 0.06. The EPS decreased by -28.75% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 1.92% | ||
| ROA | 0.85% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
MNKD Ownership
MNKD Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.01 | 375.559B | ||
| AMGN | AMGEN INC | 15.38 | 191.693B | ||
| GILD | GILEAD SCIENCES INC | 15.72 | 176.393B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.5 | 113.496B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.02 | 81.177B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 43.17 | 42.608B | ||
| INSM | INSMED INC | N/A | 34.4B | ||
| NTRA | NATERA INC | N/A | 28.771B | ||
| BIIB | BIOGEN INC | 10.76 | 25.993B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.14 | 25.192B | ||
| MRNA | MODERNA INC | N/A | 20.253B | ||
| INCY | INCYTE CORP | 12.54 | 19.296B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.068B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About MNKD
Company Profile
MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. The company is headquartered in Danbury, Connecticut and currently employs 592 full-time employees. The company went IPO on 2004-07-28. Focused on cardiometabolic and orphan lung diseases, it develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. Its commercial assets include Afrezza, FUROSCIX and V-Go along with Tyvaso DPI. Its commercializing Afrezza (insulin human) Inhalation Powder, an ultra-rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease product, Tyvaso DPI (treprostinil) inhalation powder, is used in the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Company Info
IPO: 2004-07-28
MANNKIND CORP
1 Casper Street
Danbury CONNECTICUT 91362 US
CEO: Michael E. Castagna
Employees: 592
Phone: 18009279800
MANNKIND CORP / MNKD FAQ
What does MNKD do?
MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. The company is headquartered in Danbury, Connecticut and currently employs 592 full-time employees. The company went IPO on 2004-07-28. Focused on cardiometabolic and orphan lung diseases, it develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. Its commercial assets include Afrezza, FUROSCIX and V-Go along with Tyvaso DPI. Its commercializing Afrezza (insulin human) Inhalation Powder, an ultra-rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease product, Tyvaso DPI (treprostinil) inhalation powder, is used in the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Can you provide the latest stock price for MANNKIND CORP?
The current stock price of MNKD is 2.57 USD. The price increased by 0.39% in the last trading session.
Does MNKD stock pay dividends?
MNKD does not pay a dividend.
What is the ChartMill technical and fundamental rating of MNKD stock?
MNKD has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
Can you provide the PE ratio for MNKD stock?
The PE ratio for MANNKIND CORP (MNKD) is 42.83. This is based on the reported non-GAAP earnings per share of 0.06 and the current share price of 2.57 USD.
Is MANNKIND CORP (MNKD) expected to grow?
The Revenue of MANNKIND CORP (MNKD) is expected to grow by 36.86% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the next earnings date for MNKD stock?
MANNKIND CORP (MNKD) will report earnings on 2026-05-06, after the market close.